Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Helix Biomedix's share price is $1.79.
Helix Biomedix's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2012 was $12.45. Hence, Helix Biomedix's PS Ratio for today is 0.14.
The historical rank and industry rank for Helix Biomedix's PS Ratio or its related term are showing as below:
HXBM's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.3 * Ranked among companies with meaningful PS Ratio only.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Helix Biomedix PS Ratio Related Terms
Helix Biomedix PS Ratio Historical Data
* Premium members only.
The historical data trend for Helix Biomedix's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Helix Biomedix's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helix Biomedix PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helix Biomedix's PS Ratio distribution charts can be found below:
* The bar in red indicates where Helix Biomedix's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Helix Biomedix's Share Price of today is $1.79. Helix Biomedix's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.45.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Helix Biomedix (HXBM) has a PS Ratio of 0.14 as of Jul. 18, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Helix Biomedix and its competitors.
Is Helix Biomedix's PS Ratio too high?
Helix Biomedix's current PS Ratio is 0.14. The Biotechnology industry median PS Ratio is 9.30. Helix Biomedix's value of 0.14 is 98.5% below this industry median.
How does Helix Biomedix's PS Ratio compare to XBIO and CBLI?
Helix Biomedix's PS Ratio of 0.14 can be compared against companies in the Biotechnology industry. The industry median PS Ratio is 9.30. Helix Biomedix's value of 0.14 is 98.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.30, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Helix Biomedix's current PS Ratio of 0.14 is 98.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Helix Biomedix and its competitors. For the Biotechnology industry, the median PS Ratio is 9.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helix Biomedix's current PS Ratio is 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix Biomedix stock overvalued right now?
Helix Biomedix (HXBM) has a current PS Ratio of 0.14. The current PS Ratio is 0.14 and 98.5% below the Biotechnology industry median of 9.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Helix Biomedix (HXBM), the current PS Ratio is 0.14 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helix Biomedix Inc is a Delaware-based biopharmaceutical company that focuses on the early-stage development of peptide-based therapeutics for dermatology and skin health. The Company is in the preclinical stage, advancing a rare disease drug program for xeroderma pigmentosum, and plans to seek orphan drug designation before entering clinical development. Leveraging its proprietary peptide technology, Helix BioMedix aims to address unmet needs in rare dermatological conditions and has a history of developing patented bioactive peptides for topical personal care use.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HXBM has been successfully added to your 
